7:12 PM
 | 
Jun 04, 2007
 |  BC Extra  |  Company News

JNJ refund offer triggers NICE Velcade rethink

Following an offer by Johnson & Johnson (JNJ) to only charge for those patients that benefit from Velcade bortezomib, the U.K.'s National Institute of Health and Clinical Excellence issued a draft guidance recommending National Health Service (NHS) use of the drug for patients with multiple myeloma (MM) who have received at least one prior therapy....

Read the full 262 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >